People who start treatment with Tysabri (natalizumab) soon after being diagnosed with multiple sclerosis (MS) are at a lower risk of relapse in the long term compared with patients who start on less effective disease-modifying therapies (DMT), a study has found. Patients on Tysabri, an antibody-based therapy,…

High-efficacy therapies given early can significantly reduce the risk of disability worsening in children and adolescents with multiple sclerosis (MS), particularly when treatment is started while patients have fairly minimal disability, according to a new study. While lower-efficacy therapies were also associated with a reduced risk of disability progression…

Children with multiple sclerosis (MS) who start on high-efficacy therapies experience fewer relapses and reduced MRI disease activity in the following years, compared with those who are treated first with moderate-efficacy therapies, according to a new study. Rates of severe side effects are similar for both groups, but the…

Use of high-efficacy therapies can lower the risk of disability progression in people with childhood-onset multiple sclerosis (MS), particularly if given in early disease stages when disabling symptoms are negligible. That’s according to data shared at the 9th joint meeting of the European Committee for Treatment and…

People with relapsing-remitting multiple sclerosis (RRMS) who had an early start on high-efficacy disease-modifying therapies (DMTs) experience slower disability progression compared with those on escalation treatment, according to recent research. The study, which followed patients for up to 10 years, supports starting high-risk RRMS patients on highly effective…

Outcomes are better for people with relapsing-remitting multiple sclerosis (RRMS) initially treated with higher efficacy disease-modifying therapies (DMTs) than for those who begin with lower efficacy DMTs and escalate to more effective treatments as the disease progresses, according to a real-world analysis of patient registry data. Findings also…

Neurologists in the U.S. are generally favoring more aggressive early treatment for multiple sclerosis (MS), according to an analysis by market research company Spherix Global Insights. With over a dozen therapies available in the U.S. to treat relapsing forms of MS, patients and providers have options to…

Exposure to high-efficacy disease-modifying therapies (DMTs) is associated with an increased risk of cervical abnormalities in women with multiple sclerosis (MS), recent data suggest. The findings are consistent with previous reports showing these treatments may raise the risk of certain cancers, likely as a consequence of their immune-modulating…

People with relapsing multiple sclerosis (MS) treated with Tysabri (natalizumab) or Gilenya (fingolimod) are less likely to have disease activity than those on low-efficacy MS medications, according to a small study conducted in Japan. Results also showed that patients receiving the high-efficacy therapies had less brain shrinkage,…

Tysabri (natalizumab) outperforms other disease-modifying therapies (DMTs) in its ability to lessen a range of patient-reported symptoms in people with multiple sclerosis (MS), according to data from a large real-world study. These symptoms include balance difficulties, sensory problems, feelings of anxiety, bladder problems, vision problems, and…

People with relapsing-remitting multiple sclerosis (RRMS) in Sweden have lower rates of worsening disability than those who live in Denmark, likely due to differences in treatment strategies in each country, according to a new study. “This study shows that, for the first time to our knowledge, differences in national…

Using high-efficacy therapies as a first treatment for multiple sclerosis (MS) patients significantly increases the likelihood of having no evidence of disease activity after one and two years, compared to using moderately effective therapies, according to a real-world study of Norwegian patients. However, with each additional attempted treatment, the…